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Background. The interleukin 10 (IL-10) family comprises cytokines structurally related to IL-10 that share
signaling receptors that have conserved signaling cascades. The immunopathogenesis of immune reconstitution
inﬂammatory syndrome (IRIS) in patients with human immunodeﬁciency virus (HIV) infection and tuberculosis
remains incompletely understood. We hypothesized that a deﬁciency of IL-10 and its homologs may contribute to
the immunopathology of IRIS in these patients.
Methods. We performed a case-control analysis involving patients with HIV infection and tuberculosis who had
IRIS at clinical presentation (tuberculosis-IRIS) and similar patients with HIV infection and tuberculosis who did not
develop tuberculosis-IRIS (non-IRIS). Peripheral blood mononuclear cells (PBMCs) were cultured in the presence or
absence of heat-killed Mycobacterium tuberculosis for 6 and 24 hours. Messenger RNA was analyzed by quantitative
reverse transcription polymerase chain reaction analysis. Cytokine concentrations in serum were also determined.
Results. Cultures of PBMCs stimulated with M. tuberculosis for 24 hours yielded higher IL-10 and interleukin 22
(IL-22) transcript levels for tuberculosis-IRIS patients, compared with non-IRIS patients. Analysis of corresponding
serum samples showed signiﬁcantly higher concentrations of IL-10 and IL-22 in tuberculosis-IRIS patients, compared
with non-IRIS patients.
Conclusions. IL-10 and IL-22 were differentially induced in PBMCs from tuberculosis-IRIS patients after in vitro
stimulation, and higher concentrations of their corresponding proteins were detected in serum (in vivo). The higher
levels of IL-10 observed in this study may represent a compensatory antiinﬂammatory response during tuberculosis-
IRIS. The elevated levels of IL-22 suggest an association between this cytokine and immunopathology during tubercu-
losis-IRIS.
Keywords. tuberculosis; HIV-1; complications; immune response; interleukin-10; drug therapy; immune
reconstitution inﬂammatory syndrome; interleukin-22; interleukin-26.
The immune reconstitution inﬂammatory syndrome
(IRIS) is a commonly encountered immunological
complication of the combined therapies for human
immunodeﬁciency virus type 1 (HIV-1) infection and
tuberculosis [1, 2]. Two forms of tuberculosis-associa-
ted IRIS (tuberculosis-IRIS) exist. The condition is
best recognized as a paradoxical immune-mediated
worsening of tuberculosis symptoms and other symp-
toms occurring in patients prescribed combined anti-
tubercular and antiretroviral therapy [3, 4]. Common
clinical manifestations of tuberculosis-IRIS include
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recurrent tuberculosis symptoms, fever, and enlarging and
suppuration of lymph nodes [4]. Understanding of the immu-
nopathogenesis of tuberculosis-IRIS remains incomplete, al-
though it has become the subject of increased investigation in
recent years.
We previously investigated the involvement of multiple cy-
tokines and demonstrated that paradoxical tuberculosis-IRIS
is associated with hypercytokinemia [5, 6]. The interleukin 10
(IL-10) family comprises cytokines structurally related to IL-
10, such as interleukin 19 (IL-19), interleukin 20 (IL-20), in-
terleukin 22 (IL-22), interleukin 24 (IL-24; MDA-7), interleu-
kin 26 (IL-26; AK155), interleukin 28 (IL-28), and interleukin
29 (IL-29) in humans, in addition to some encoded in the
genomes of herpes and pox viruses [7]. IL-10–related cyto-
kines are highly pleiotropic but are linked together through
genetic similarity and intron-exon gene structure [8], although
other than the activities of IL-10, little is known about the bio-
logical activities of the IL-10 family [7]. It has been suggested
that these cytokines may participate in T-cell–mediated dis-
eases by regulation of T-cell cytokine proﬁles [9]. Human IL-
10 is the most well-characterized molecule in this group, and
it has multiple biological effects, including immunoregulatory
and antiinﬂammatory effects on different cell types. IL-10 is
produced by various immune cells, which include activated
monocytes, T cells (CD4+ and CD8+), macrophages, and den-
dritic cells [10]. IL-10 functions mainly to regulate T-helper 1
cytokines, major histocompatibility class II and B7 molecules,
and expression of costimulator molecules on macrophages
that are necessary for optimal T-cell activation [7, 8, 11]. By
inhibiting expression of these molecules on antigen-presenting
cells, IL-10 directly suppresses the activation of T cells and the
production of T-cell–derived cytokines, such as interferon γ
(IFN-γ) and interleukin 2 [11].
Similar to IL-10, the related members of the IL-10 family are
secreted as α helical proteins whose amino acid sequences are
up to 30% identical to that of IL-10, with the encoding genes
located on 2 clusters in the human genome [12, 13]. One major
similarity among these cytokines is the sharing of signaling re-
ceptors and the use of conserved signaling cascades [8].
However, knowledge of the biology of many of these IL-10 ho-
mologs remains incomplete. IL-22 is a proinﬂammatory cytokine
that plays an important role in innate pathogen defense [12,14].
Expression of IL-22 has been shown to be highest in activated
memory CD4+ T cells and lowest in activated natural killer
cells [8], with little or no expression observed in other immune
cells [13]. The preferential production of IL-22 by T cells sug-
gests that increased expression of this cytokine may occur in T-
cell–mediated diseases [8]. IL-22 acts on nonimmune cells and
has been linked with severe inﬂammation in chronic T-cell–
mediated inﬂammatory diseases, such as psoriasis, Crohn
disease, and rheumatoid arthritis [12, 13]. IL-22 also contributes
to the human antimycobacterial immune response [15, 16].
The resolution of inﬂammation is dependent on the host’s
ability to mount an immunoregulatory response to regulate
the magnitude of inﬂammatory responses. IRIS results from
excessive pathological immune responses occurring during
immune recovery in HIV-infected patients who are commenc-
ing antiretroviral therapy (ART). In this study, we therefore
hypothesized that IL-10 and its homologs may be deﬁcient
and that this immune dysregulation may be involved in the
immunopathology associated with tuberculosis-IRIS.
METHODS
Ethical approval for these studies was provided by the Univer-
sity of Cape Town Research Ethics committee (REC references
337/2004 and 173/2005). Participants were recruited at
G. F. Jooste Hospital and at the Ubuntu Clinic, Site B Khaye-
litsha, in Cape Town, South Africa, between March 2005 and
December 2007 to 2 prospective studies whose designs have
been previously reported [17, 18]. Patients had a conﬁrmed di-
agnosis of paradoxical tuberculosis-IRIS that was based on the
International Network for the Study of HIV-associated IRIS
consensus case deﬁnition [3], which has been independently
validated [19–21]. Patients were >18 years of age, not preg-
nant, and ART naive. Known rifampicin-resistant tuberculosis
was an exclusion criterion. At entry into these studies, a clini-
cal diagnostic work-up was performed to exclude an alterna-
tive diagnosis for clinical deterioration.
Cross-sectional Analysis of Paradoxical Tuberculosis-IRIS
and Non-IRIS Patients
For the case-control analysis, 20 patients (of 32 available) with
paradoxical tuberculosis-IRIS were selected randomly from
participants who were enrolled at the time of diagnosis with
paradoxical tuberculosis-IRIS. Cases were matched with 20
non-IRIS controls who were enrolled using similar criteria
(CD4+ T-cell count, age, sex, and duration of anti-tuberculosis
treatment) but did not develop tuberculosis-IRIS 2 weeks after
starting combination ART (cART). The study design, patient
selection criteria, and treatment regimens have been previous-
ly described [5].
Blood Processing and Cell Cultures
Peripheral blood mononuclear cells (PBMCs) were isolated
using Ficoll from 30 mL of blood collected in Na-heparin BD
vacutainers and were plated at 2.5 × 106 cells/well. PBMCs were
restimulated with heat-killed H37Rv Mycobacterium tuberculo-
sis for 6 or 24 hours at a multiplicity of infection (MOI) of 1:1.
After incubation, PBMCs were harvested and lysed for RNA
extraction. Cell lysates from both the 6- and 24-hour time
points were stored for RNA analysis. Serum was also collected
and cryopreserved at −80°C until further analysis.
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Quantitative Reverse Transcription Polymerase Chain Reaction
(qRT-PCR)
Messenger RNA (mRNA) was extracted from PBMC lysates by
using the RNeasy Mini Kit Spin Protocol (Qiagen, Valencia,
CA) in accordancewith themanufacturer’s recommendations and
was cryopreserved at −80°C until further analysis. Primers and
probes were purchased from Applied Biosystems as inventoried
TaqMan Gene Expression Assays (Applied Biosystems, Qiagen,
Valencia, CA). The TaqMan RNA-Ct 1 Step kit protocol was
used in these assays. A lower difference in cycle threshold (ΔCt)
indicates a higher transcript abundance. Fold-induction was
used to obtain a relative measure of gene induction by M. tuber-
culosis and was determined using the ΔΔCt method.
Analysis of Cytokine Levels in Serum Samples
The level of soluble IL-10 protein in serum samples was mea-
sured using customized commercial Milliplex XMAP kits,
whereas the level of IL-22 was measured using the human IL-
22 Immunoassay Quantikine ELISA kit from R&D Systems
(Minneapolis, MN).
Flow Cytometric Analysis
Frozen PBMCs from 4 patients with tuberculosis-IRIS were
thawed, resuspended in Roswell Park Memorial Institute
medium (Sigma, UK) with 10% heat-inactivated fetal calf
serum (FCS; Sigma, UK), and stimulated with heat-killed M.
tuberculosis H37Rv (hkH37Rv; MOI 1:1) for 4 hours at 37°C
in 5% CO2. Brefeldin A (10 μg/mL; Sigma, UK) was added to
each tube, vortexed, and incubated for a further 20 hours.
After 24 hours, cells were washed twice with phosphate-buff-
ered saline (PBS; Sigma, UK) and stained for surface CD3-
FITC and CD14-APC (both from BD Biosciences) for 30
minutes in the dark at 4°C. PBMCs were washed in ﬂuores-
cence-activated cell sorter (FACS) wash buffer (PBS with 0.5%
FCS); BD Cytoﬁx/Cytoperm was then added, and PBMCs
were incubated for 20 minutes in the dark at 4°C. PBMCs
were washed with 1X BD Perm Wash and stained for intracel-
lular IL-10-PE (BD Biosciences) and IL-22-PerCP-eFluor 710
(eBiosciences) for 1 hour at 4°C in the dark. Cells were
washed 3 times with 1X BD Perm Wash buffer and acquired
on a BD FACS Calibur. Analysis was performed using FlowJo,
v9.4.3 (available at: http://www.treestar.com).
RESULTS
Baseline Characteristics of Participants
A total of 20 patients with paradoxical tuberculosis-IRIS and 20
non-IRIS controls were analyzed. Supplementary Table 1 shows
a summary of the baseline demographic and clinical character-
istics for the patients analyzed in this study. The 2 groups of
patients were well matched with respect to sex, age, and baseline
CD4+ T-cell count. There were no signiﬁcant differences
between the tuberculosis-IRIS and non-IRIS groups in terms of
previous tuberculosis, tuberculosis form, and median days from
cART initiation to IRIS onset (or to sample collection, in the
case of non-IRIS controls). However, tuberculosis-IRIS patients
were more likely to have a shorter duration between tuberculo-
sis treatment and commencement of cART (P = .028).
Transcript Abundance of IL-10–Related Genes
PBMCs from 20 tuberculosis-IRIS patients and 20 non-IRIS
controls were cultured in the presence or absence of heat-
killed H37Rv M. tuberculosis antigen for 6 and 24 hours. Eval-
uation at 6 hours revealed that M. tuberculosis stimulation had
increased the transcript abundance of several of the cytokines
in both the tuberculosis-IRIS and non-IRIS groups (Table 1).
A lower ΔCt indicates a higher transcript abundance. Signiﬁ-
cantly higher transcript levels were observed for IL-22 in tu-
berculosis-IRIS patients after stimulation (P = .009), whereas
levels of IL-24 transcripts were higher for non-IRIS patients
(P = .020). IL-10 levels were signiﬁcantly higher in unstimu-
lated non-IRIS cultures (P = .04) and increased more in tuber-
culosis-IRIS cultures, compared with non-IRIS cultures, after
stimulation. IL-26 transcript levels were signiﬁcantly higher in
both stimulated and unstimulated cultures of tuberculosis-
IRIS PBMCs (P = .008 and P = .042, respectively). IL-28 tran-
script levels did not differ between unstimulated tuberculosis-
IRIS and non-IRIS cultures but increased signiﬁcantly in non-
IRIS cultures after stimulation (P = .013).
At 24 hours, several of the cytokines (IL-10, IL-20, and IL-
26) had signiﬁcantly higher transcript levels in the stimulated
tuberculosis-IRIS cultures (P < .001, P = .022, and P = .004, re-
spectively). IL-22 transcript levels were higher in both stimu-
lated and unstimulated tuberculosis-IRIS cultures (P = .004
and P = .015, respectively). IL-28 transcript levels were signiﬁ-
cantly higher in unstimulated non-IRIS PBMCs (P = .012) but
not in stimulated cultures. In PBMCs from both tuberculosis-
IRIS and non-IRIS patients, M. tuberculosis stimulation result-
ed in increased transcript abundance for many of the cyto-
kines, most prominently IL-19, IL-20, IL-24, and IL-26
(Table 2).
Fold-Induction Analysis of IL-10–Related Genes
IL-10 mRNA was highly and signiﬁcantly induced in tubercu-
losis-IRIS patients at 6 hours and more so at 24 hours (P = .04
and P = .0002, respectively; Figure 1). Similarly, IL-22 was
found to be signiﬁcantly upregulated at both 6 and 24 hours
in cultures from tuberculosis-IRIS patients, compared with
non-IRIS control patients (P = .004 and P = .0015, respective-
ly). Although both IL-19 and IL-20 were highly induced by M.
tuberculosis stimulation, no signiﬁcant differences were ob-
served when comparing mRNA from tuberculosis-IRIS pa-
tients and mRNA from non-IRIS patients in cultures from the
6- and 24-hour time points. Although IL-24 tended to be
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more induced in cultures for the non-IRIS group at both time
points, the difference between the tuberculosis-IRIS and non-
IRIS groups was not signiﬁcant. Similarly, there were no sig-
niﬁcant differences observed between tuberculosis-IRIS and
non-IRIS patients at either time point for IL-26, although
there tended to be more induction of IL-26 in the tuberculo-
sis-IRIS patients at 24 hours. IL-28 and IL-29 were seldom ex-
pressed at high levels in these samples, and no signiﬁcant
differences were observed between induction/repression in the
2 patient groups. Although IL-29 was marginally detectable at
6 hours, it was not detectable at 24 hours (Figure 1).
Analysis of Serum Cytokine Levels
To further investigate the RNA results, protein concentrations
were determined in serum samples for genes that showed con-
sistent and signiﬁcant differences in the mRNA analysis (ie,
Table 1. Cycle Threshold Differences (ΔCt) for Interleukin 10 (IL-10)–Related Cytokine Genes After 6 Hours of In Vitro Stimulation
With Heat-Killed Mycobacterium tuberculosis
Cytokine
P
Unstimulated PBMCs, by Study
Group, Median (IQR)
Stimulated PBMCs, by Study
Group, Median (IQR)
Tuberculosis-IRIS vs
Non-IRIS Unstimulated vs Stimulated
Tuberculosis-IRIS Non-IRIS Tuberculosis-IRIS Non-IRIS Unstimulated Stimulated Tuberculosis-IRIS Non-IRIS
IL-10 7.2 (6.4–8.2) 6.6 (5.8–7.6) 5.9 (3.4–7.1) 6.1 (5.0–7.5) .04 .25 .003 .27
IL-19 13.4 (5.5–17.8) 13.6 (10.8–19.2) 8.8 (6.5–11.6) 8.4 (5.1–12.1) .935 .804 <.0001 <.0001
IL-20 18.9 (11.2–21.3) 18.4 (9.6–21.2) 14.3 (10.6–19.8) 13.2 (8.5–18.8) .236 .103 <.0001 <.0001
IL-22 19.5 (15.6–21.6) 18.6 (13.8–21.3) 13.0 (8.3–20.5) 17.1 (10.1–21.4) .073 .009 <.0001 .086
IL-24 14.1 (7.6–20.8) 13.3 (5.8–18.3) 11.8 (7.7–15.7) 9.5 (5.9–13.7) .625 .020 .001 <.0001
IL-26 16.9 (14.4–20.0) 18.6 (17.1–21.0) 16.4 (11.3–19.4) 17.5 (13.0–20.7) .008 .042 .002 .010
IL-28 11.6 (8.6–16.3) 11.7 (9.7–13.0) 12.5 (10.1–14.3) 11.4 (8.8–12.8) .882 .013 .351 .130
Data are for patients with HIV infection and tuberculosis who had IRIS at clinical presentation (tuberculosis-IRIS) and similar patients with HIV infection and
tuberculosis who did not develop tuberculosis-IRIS (non-IRIS). At 6 hours, levels of IL-22 transcripts in stimulated PBMC cultures were significantly higher in
tuberculosis-IRIS patients, whereas levels of IL-24 transcripts stimulated cultures were higher in non-IRIS patients. IL-26 had significantly higher transcript levels
in both stimulated and unstimulated PBMC cultures for tuberculosis-IRIS patients. Levels of IL-28 transcripts were marginally higher in the stimulated PBMC
cultures for non-IRIS patients (P = .013). IL-29 transcripts were barely detectable (results not shown). A lower ΔCt indicates a higher transcript abundance.
Abbreviations: HIV, human immunodeficiency virus; IL-19, interleukin 19; IL-20, interleukin 20; IL-22, interleukin 22; IL-24, interleukin 24; IL-26, interleukin 26;
IL-28, interleukin 28; IQR, interquartile range; IRIS, immune reconstitution inflammatory syndrome; PBMC, peripheral blood mononuclear cell.
Table 2. Cycle Threshold Differences (ΔCt) for Interleukin 10 (IL-10)–Related Cytokine Genes After 24 Hours of In Vitro Stimulation
With Heat-Killed Mycobacterium tuberculosis
Cytokine
P
Unstimulated PBMCs, by Study
Group, Median (IQR)
Stimulated PBMCs, by Study
Group, Median (IQR)
Tuberculosis-IRIS vs
Non-IRIS Unstimulated vs Stimulated
Tuberculosis-IRIS Non-IRIS Tuberculosis-IRIS Non-IRIS Unstimulated Stimulated Tuberculosis-IRIS Non-IRIS
IL-10 6.9 (5.1–8.1) 6.9 (6.0–7.1) 4.9 (3.1–6.4) 6.8 (5.9–8.5) .74 <.001 <.001 1.0
IL-19 11.7 (2.3–16.9) 10.9 (4.3–18.8) 6.9 (2.9–10.1) 5.9 (2.0–18.2) .472 .433 <.0001 .0002
IL-20 14.0 (7.9–19.1) 16.2 (4.3–20.8) 9.6 (5.9–15.9) 12.5 (6.4–19.1) .386 .028 .0003 <.0001
IL-22 18.3 (12.4–19.9) 15.5 (12.5–19.7) 12.0 (6.8–14.9) 14.7 (8.0–19.2) .004 .015 <.0001 .199
IL-24 13.2 (6.4–18.3) 13.1 (3.1–14.0) 10.4 (5.5–15.1) 9.9 (12.9–15.1) .944 .661 .007 .020
IL-26 13.1 (10.2–16.5) 13.3 (11.4–18.2) 8.4 (4.4–14.5) 11.1 (7.2–16.2) .273 .004 <.0001 .019
IL-28 10.7 (8.6–14.2) 9.7 (7.5–11.8) 10.2 (6.4–12.3) 10.2 (8.3–11.9) .012 .609 .034 .025
Data are for patients with HIV infection and tuberculosis who had IRIS at clinical presentation (tuberculosis-IRIS) and similar patients with HIV infection and
tuberculosis who did not develop tuberculosis-IRIS (non-IRIS). At 24 hours, IL-10, IL-20, and IL-26 transcript levels were significantly higher in the stimulated
cultures for tuberculosis-IRIS patients but not in unstimulated cultures. IL-22 transcript levels were higher in unstimulated non-IRIS cultures but increased
significantly after M. tuberculosis stimulation in tuberculosis-IRIS patients only (P = .015). IL-28 transcript levels were significantly higher in non-IRIS patients at
24 hours in unstimulated cultures but not in stimulated cultures. A lower ΔCt indicates a higher transcript abundance.
Abbreviations: HIV, human immunodeficiency virus; IL-19, interleukin 19; IL-20, interleukin 20; IL-22, interleukin 22; IL-24, interleukin 24; IL-26, interleukin 26;
IL-28, interleukin 28; IQR, interquartile range; IRIS, immune reconstitution inflammatory syndrome; PBMC, peripheral blood mononuclear cell.
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Figure 1. Fold-induction analysis of induction of interleukin 10 (IL-10)–related cytokines by heat-killed Mycobacterium tuberculosis. Peripheral blood
mononuclear cells (PBMCs) from 20 patients with human immunodeﬁciency virus (HIV) infection and tuberculosis who had immune reconstitution
inﬂammatory syndrome (IRIS) at clinical presentation (tuberculosis-IRIS) and 20 control patients with HIV infection and tuberculosis who did not develop
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IL-10 and IL-22). Signiﬁcantly higher concentrations of IL-10
(P = .0004; Figure 2) were detected in the serum of tuberculo-
sis-IRIS patients (median, 875.6 pg/mL [interquartile range
{IQR}, 64.5–9982 pg/mL]), compared with non-IRIS patients
(median, 137.2 pg/mL [IQR, 24.3–1346 pg/mL]). Similarly,
signiﬁcantly higher levels of IL-22 (P = .007) were detected in
the serum samples of tuberculosis-IRIS patients (median, 53.2
pg/mL [IQR, 11.31–188.8 pg/mL]), compared with non-IRIS
patients (median, 24.4 pg/mL [IQR, 15.7–43.8 pg/mL]).
Correlation of IL-10 and IL-22 Serum Concentrations
To determine whether the elevated concentrations of IL-10
and IL-22 observed in the serum samples of tuberculosis-IRIS
patients correlated, Spearman correlation was calculated.
There was an inverse correlation between the serum concen-
trations of IL-10 and IL-22 (Spearman r = −0.69; P = .007) in
the tuberculosis-IRIS group. However, no signiﬁcant correla-
tion was observed in the non-IRIS group (Spearman
r = −0.07; P = .83).
Cellular Origin of IL-10 and IL-22
To investigate the cellular origin of IL-10 and IL-22 in tuber-
culosis-IRIS patients, frozen PBMCs from 4 patients who
presented with IRIS were stimulated with heat-killed M. tuber-
culosis H37Rv (MOI 1:1) for 4 hours, followed by addition of
brefeldin A for a further 20 hours. At this time, cells were
stained for surface CD3 and CD14. Cells were then stained for
intracellular IL-10 and IL-22. We found that CD14+ cells were
more likely to be positive for IL-22 (median, 0.6% [IQR,
0.02%–2.1%]), compared with CD3+ lymphocytes (median,
0.02% [IQR, 0%–0.04%]). The difference was not statistically
signiﬁcant, owing to the small number of samples. Similarly,
CD14+ cells were also more likely to be positive for IL-10
(median, 0.06% [IQR, 0%–0.15%), compared with CD3+ cells
(median, 0% [IQR, 0%–0.01%]).
DISCUSSION
Our analysis of IL-10–related cytokines showed an increase in
the transcript levels of IL-10 and IL-22 in tuberculosis-IRIS
patients, compared with non-IRIS controls. The correspond-
ing serum samples showed signiﬁcantly higher concentrations
of IL-10 and IL-22 protein in tuberculosis-IRIS patients. Thus,
our hypothesis that IRIS is associated with depressed IL-10 re-
sponses was falsiﬁed, as the opposite appears to have been the
Figure 1 continued. tuberculosis-IRIS (non-IRIS) were cultured in the presence or absence of M. tuberculosis for 6 and 24 hours and then lysed for
messenger RNA transcript analysis by quantitative reverse transcription polymerase chain reaction. Fold-induction of the genes was determined using
the ΔΔ cycle threshold method. This method compares the difference in the cycle threshold between the gene of interest to that of a normalization
gene (β-actin). IL-10 and interleukin 22 (IL-22) were differentially induced in tuberculosis-IRIS patients at both 6 and 24 hours. For interleukin 19 (IL-19),
interleukin 20 (IL-20), interleukin 24 (IL-24), interleukin 26 (IL-26), interleukin 28 (IL-28), and interleukin 29 (IL-29), no signiﬁcant differences were noted
between tuberculosis-IRIS and non-IRIS patients, irrespective of restimulation of PBMCs with M. tuberculosis. Tuberculosis-IRIS patients are represented
by the black boxes, whereas the open white boxes represent non-IRIS patients.
Figure 2. Analysis of interleukin 10 (IL-10) and interleukin 22 (IL-22) concentrations in serum. Consistent with the fold-induction analysis, IL-10 and IL-22
protein levels were differentially higher in the serum of patients with human immunodeﬁciency virus (HIV) infection and tuberculosis who had immune
reconstitution inﬂammatory syndrome (IRIS) at clinical presentation (tuberculosis-IRIS). Tuberculosis-IRIS patients are shown by the white circles, whereas
the open black circles represent the control patients with HIV infection and tuberculosis who did not develop tuberculosis-IRIS (non-IRIS).
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case. Whereas analysis of fold-induction showed signiﬁcant
induction of IL-19, IL-20, IL-24, and IL-26 by M. tuberculosis,
the differences detected between the tuberculosis-IRIS and
non-IRIS groups were neither great nor statistically signiﬁcant.
Whereas the regulatory role of IL-10 in vitro and in animal
models is well documented, the role of this cytokine in clinical
situations, particularly in infectious diseases, remains the subject
of investigation [9]. Production of IL-10 can also be stimulated
by bacteria, viruses, and parasites and is regulated both at the
transcriptional and translation levels. The absence of IL-10 in
knockout mice results in reduced M. tuberculosis loads in the
lung. However, this reduction was preceded by an accelerated
and enhanced IFN-γ response in the lung, an increased inﬂux of
CD4+ T cells into the lung, and enhanced production of chemo-
kines and cytokines, including CXCL10 and IL-17, in both the
lung and the serum [22]. This suggests that, although the early
production of IL-10 in response to tuberculosis may be detri-
mental, this cytokine is ultimately necessary to prevent
immunopathology.
IL-10 has been reported to modulate the innate and adap-
tive immune responses, potentially creating a favorable envi-
ronment for the persistence of microbes, intracellular
pathogens, and chronic infections [9]. The increased ability of
macrophages to produce IL-10 when stimulated with Toll-like
receptor ligands is also associated with an increased tendency
to develop primary progressive tuberculosis [22]. Production
of IL-10 has also been reported to be higher in patients who
had active tuberculosis, compared with tuberculin skin test re-
sponders [23]. In this study, we show that consistently higher
levels of IL-10 mRNA and serum protein were observed in
tuberculosis-IRIS patients. Tuberculosis-IRIS is a highly in-
ﬂammatory condition. We hypothesize that the high levels of
IL-10 observed in the peripheral blood of tuberculosis-IRIS
patients in this study reﬂect an overspill of IL-10 from the
sites of inﬂammation where IL-10 would be involved in regu-
lating and resolving inﬂammation.
Other human studies have shown that IL-10 may be associ-
ated with susceptibility to infections caused by rapidly
growing mycobacteria [24]. Signiﬁcantly higher levels of circu-
lating IL-10 have been demonstrated in HIV-infected patients
than in healthy controls [25]. IL-10 production has previously
been shown to increase in Mycobacterium avium–stimulated
monocytes from HIV-infected patients, with the highest ex-
pression observed in patients with advanced AIDS [24].
It is interesting that levels of IL-22 gene expression and
serum protein were, like those of IL-10, found to be signiﬁ-
cantly higher in tuberculosis-IRIS patients. IL-22 is implicated
in T-lymphocyte disease, innate pathogen defense, and acute
phase responses [9] and has been associated with increased
innate immunity in tissues [13], with expression being higher
in outer body barriers, such as skin, the respiratory system,
and the digestive system. Previous work on IL-22 and IL-17 in
tuberculosis immunity has demonstrated elevated levels of IL-
22 in the bronchoalveolar lavage ﬂuid of pulmonary tubercu-
losis patients [15]. We show that IL-22 may be implicated not
only in tuberculosis pathology, but also in tuberculosis-IRIS
immunopathology, as indicated by the higher concentrations
of IL-22 we observed in tuberculosis-IRIS patients. The coex-
pression of IL-10 and IL-22 seen in our study and their
inverse correlation in tuberculosis-IRIS patients supports the
suggestion that there may be interaction between these cytokines
in this condition (and not in controls), as has been postulated
for other diseases [26]. We also performed preliminary analysis
of the cellular source of IL-10 and IL-22 and found both more
frequently in CD14+ cells (Table 3), consistent with increasing
evidence that innate immune system activation is a component
of the immunopathology of tuberculosis-IRIS [5, 27–30].
IL-19, like IL-20, has been shown to be produced under in-
ﬂammatory conditions and is thought to play an important
role in the pathogenesis of some inﬂammatory diseases, such
as psoriasis. It has been suggested that these cytokines may be
important in autoimmune diseases and may enhance antibac-
terial and antiviral immunity [8]. However, from our study,
we did not show a link between IL-19 or IL-20 with tuberculo-
sis-IRIS immunopathology.
A major strength of our study was close matching of patients
with paradoxical tuberculosis-IRIS and controls who did not
develop the condition. Apart from the longer duration between
initiating tuberculosis treatment and ART in the non-IRIS group,
the groups were well matched. We acknowledge some limitations
to our study, an important one of which is the insufﬁciency of
24-hour tissue culture supernatants from these patients. This
Table 3. Cellular Sources of Interleukin 10 (IL-10) and Interleukin 22 (IL-22)
Cells (n = 4)
IL-10 IL-22
Unstimulated hkH37Rv (1:1) Unstimulated hkH37Rv (1:1)
CD14+ 0 (0–0.6) 0.06 (0–0.15) 0 (0–0.01) 0.6 (0.02–2.1)
CD3+ 0 (0–0.01) 0 (0–0.01) 0.01 (0–0.03) 0.02 (0–0.04)
Data are median % (interquartile range) of positive cells.
Abbreviation: hkH37Rv, heat-killed Mycobacterium tuberculosis H37Rv.
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may have limited our ability to validate and conﬁrm the mRNA
transcript ﬁndings.
In summary, our ﬁndings show elevated levels of IL-10 and
IL-22 in patients with tuberculosis-IRIS. The higher levels of
IL-10 may represent compensatory antiinﬂammatory and
immune-regulatory responses, whereas elevated IL-22 levels
suggest an association with immunopathology in tuberculosis-
IRIS.
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